Merck KGaA: New CEO, New Logo, No Serono
This article was originally published in Scrip
Merck KGaA has a new CEO and a new logo. 'German Merck' has promoted its deputy CEO Stefan Oschmann into the top job, and he will take over from Karl-Ludwig Kley in April 2016. Meanwhile, Merck is eliminating its Merck Serono and Merck Millipore brands, and will be known simply as Merck outside North America. Inside North America, where 'US Merck' owns the brand name, it will continue to use the EMD prefix for its businesses.
You may also be interested in...
Germany's Merck Group plans to bolster its biopharma R&D activities in Britain - despite Brexit - on grounds the UK is too key and dynamic a player in the life sciences sphere not to - and because the conglomerate needs to be there to help ensure its evolution into a top oncology and immuno-oncology innovator.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.